Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for tildrakizumab

  1. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575

  2. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  3. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907

  4. What are the costs associated with best supportive care?

    Source guidance details Comes from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575

    Research recommendation
    Published
    16 August 2019

  5. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153